485 completed, 86 unknown, 75 terminated, 71 recruiting. 828 Phase 2, 137 Phase 1, 71 Phase 3.
Follow Basal Ganglia Diseases: new trials by email Literature Review of Basal Ganglia Diseases trials Research Report on Basal Ganglia Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Terazosin And Metabolic Energetics in Parkinson's Disease Terazosin 5 MG, Placebo - Parkinson's Disease (PD) | Phase 2 | Suspended | Ergun Y. Uc | 120 | 2028-07-01 | 2026-10-09 |
| Study to Evaluate the Safety, Tolerability, Efficacy, and PK of FHL-301 in Parkinson's Disease Patients. Gemfibrozil, Placebo - Parkinson Disease | Phase 2 | Withdrawn | Forest Hills Lab | 2027-11-01 | 2026-08-19 | |
| Terazosin for Dementia With Lewy Bodies Terazosin Hydrochloride, Placebo - Dementia With Lewy Bodies | Phase 1 / Phase 2 | Not yet recruiting | Qiang Zhang | 40 | 2027-10-01 | 2026-03-12 |
| A Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects With Early Parkinson's Disease MT101-5 - Parkinson's Disease | Phase 2 | Not yet recruiting | Mthera Pharma Co., Ltd. | 120 | 2027-09-01 | 2026-10-16 |
| Sustained Release Oral Formulation For Treatment Of Parkinsons Disease Formulation A, Formulation B, Formulation C - Healthy Volunteers | Phase 1 / Phase 2 | Not yet recruiting | University of Minnesota | 32 | 2027-04-01 | 2026-10-01 |
| A Study of AB-1005 Gene Therapy in Japanese Adults With Moderate Parkinson's Disease (J-REGENERATE-PD) AB-1005 - Parkinson Disease | Phase 2 | Not yet recruiting | Bayer | 8 | 2027-01-25 | 2026-07-29 |
| Estimates of the Efficacy of Talineuren (TLN) and Placebo in Patients With Parkinson Disease Talineuren, Placebo - Parkinson Disease | Phase 2 | Not yet recruiting | InnoMedica Schweiz AG | 40 | 2027-01-01 | 2026-10-30 |
| Disease-modifying Efficacy of Sitagliptin Therapy in Early-stage Parkinson's Disease Sitagliptin, Sitagliptin placebo - Parkinson Disease | Phase 2 | Not yet recruiting | Yonsei University | 160 | 2026-12-15 | 2026-09-10 |
| A Study to Evaluate the Efficacy and Safety of ENERGI-F705 Tablets for Parkinson's Disease 60 milligrams of ENERGI-F705 Tablets, Placebo tablets, 120 milligrams of ENERGI-F705 Tablets - Parkinson's Disease (PD) | Phase 2 | Not yet recruiting | Energenesis Biomedical Co., Ltd. | 105 | 2026-12-01 | 2026-07-02 |
| Evaluation of Neuroinduced Mesenchymal Stem Cells and Mesenchymal Stem Cell-Derived Exosomes in Patients With Parkinsonism Intrathecal (IT), Intravenous - Parkinsonism or Parkinson's Disease Nos, Parkinsonism in Diseases Classified Elsewhere | Phase 2 | Not yet recruiting | Biocells Medical | 120 | 2026-11-23 | 2026-03-13 |
| Open-Label, Multi-Stage Study to Optimize the Intraputaminal Administration of AB-1005 Using a Prescriptive Infusion Algorithm (PIA) Prescriptive Infusion Algorithm, AB-1005 - PARKINSON DISEASE (Disorder) | Phase 2 | Not yet recruiting | AskBio Inc | 18 | 2026-11-01 | 2026-10-29 |
| Lemborexant on Perioperative Sleep Quality in Patients With Parkinson's Disease Undergoing Deep Brain Stimulation Lemborexant 5 mg, Placabo - Parkinson Disease (PD), Sleep Initiation and Maintenance Disorders | Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 128 | 2026-11-01 | 2026-10-29 |
| A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of NIO752 in Primary Tauopathies NIO752, Placebo - Progressive Supranuclear Palsy, Corticobasal Degeneration | Phase 2 | Not yet recruiting | Novartis Pharmaceuticals | 48 | 2026-10-23 | 2026-10-09 |
| Prevent Cognitive Decline in GBA-associated Parkinson's Disease Prasinezumab, Sodium Chloride - Parkinson's Disease | Phase 2 | Recruiting | University Hospital Tuebingen | 120 | 2026-10-01 | 2026-10-23 |
| Open-Label Access to ATH434 for Patients Who Completed Study ATH434-201 in France ATH434 - Multiple System Atrophy | Phase 2 | Enrolling by invitation | Alterity Therapeutics | 7 | 2026-10-01 | 2026-10-09 |
| Study to Test Effects and Safety of RO7568282 in Early Parkinson's Disease RO7568282, Placebo - Parkinson's Disease | Phase 1 / Phase 2 | Not yet recruiting | Hoffmann-La Roche | 474 | 2026-09-30 | 2026-10-20 |
| DaxibotulinumtoxinA for Blepharospasm Botulinum Neurotoxin Type A - Blepharospasm of Both Eyelids, Blepharospasm of Left Eyelid | Phase 2 | Recruiting | University of Pennsylvania | 20 | 2026-09-24 | 2026-09-29 |
| RESvEraTrol in Parkinson's Disease (RESET) Trans-Resveratrol - Parkinson's Disease | Phase 2 | Recruiting | Georgetown University | 30 | 2026-09-17 | 2026-09-18 |
| A Study of the Safety and Efficacy of Prime Editing (PM577) in Participants With Wilson Disease (WD) PM577a - Wilson Disease, Wilson's Disease | Phase 1 / Phase 2 | Recruiting | Prime Medicine, Inc. | 42 | 2026-09-01 | 2026-10-01 |
| Autologous Stem Cell Therapy in Patients With Multiple System Atrophy MSCs, Placebo - MSA - Multiple System Atrophy, MSA | Phase 2 | Not yet recruiting | Biocells Medical | 50 | 2026-09-01 | 2026-03-11 |
Showing 20 of 828. Sign in to see all of them.
Parkinson Disease (600) · Huntington Disease (76) · Dyskinesias (45) · Tourette Syndrome (45) · Lewy Body Disease (37) · Movement Disorders (37) · Multiple System Atrophy (35) · Neurodegenerative Diseases (31) · Supranuclear Palsy, Progressive (30) · Parkinsonian Disorders (27) · Dementia (19) · Cognitive Dysfunction (15) · Alzheimer Disease (14) · Brain Diseases (14) · Central Nervous System Diseases (13)
Nervous System Diseases (817) · Central Nervous System Diseases (815) · Brain Diseases (814) · Movement Disorders (789) · Neurodegenerative Diseases (784) · Synucleinopathies (653) · Parkinsonian Disorders (615) · Mental Disorders (217) · Pathological Conditions, Signs and Symptoms (161) · Signs and Symptoms (138) · Neurocognitive Disorders (136) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (132) · Genetic Diseases, Inborn (131) · Heredodegenerative Disorders, Nervous System (131)
Levodopa (31) · carbidopa, levodopa drug combination (23) · Carbidopa (12) · Apomorphine (10) · Donepezil (9) · mavoglurant (9) · Saline Solution (8) · istradefylline (8) · Pramipexole (7) · Sodium Chloride (7) · entacapone (7) · valbenazine (7) · Creatine (6) · Droxidopa (6) · Sugars (6)
National Institute of Neurological Disorders and Stroke (NINDS) (23) · Institute for Neurodegenerative Disorders (11) · Novartis Pharmaceuticals (10) · Chang Gung Memorial Hospital (8) · Eisai Inc. (8) · Pfizer (8) · University College, London (8) · University Hospital, Toulouse (8) · Axovant Sciences Ltd. (7) · Biogen (7) · Neurocrine Biosciences (7) · Hoffmann-La Roche (6) · Kyowa Kirin Co., Ltd. (6) · Novartis (6) · Tanta University (6)
United States (420) · France (111) · Germany (98) · United Kingdom (91) · Canada (83) · Spain (65) · Italy (63) · Poland (40) · Japan (37) · China (33) · Australia (32) · Israel (30) · Netherlands (30) · Austria (29) · South Korea (18)
Danna Jennings, MD (6) · Ilise Lombardo, MD (6) · Fernando L Pagan, MD (4) · Kyoji Imaoka, Mr (4) · Adam Boxer, MD, PhD (3) · Anne-Marie Wills, MD (3)
PMID 36463457, PMID 36602886, PMID 38588457, PMID 38489195, PMID 40680102, PMID 31356217, PMID 29480210, PMID 32250312, PMID 17941858, PMID 21484867, PMID 24001701, PMID 24144615, PMID 24412048, PMID 24711047, PMID 25988365, PMID 26763495, PMID 27214258, PMID 28202705, PMID 29029679, PMID 31381524, PMID 36811812, PMID 36849448, PMID 38072889, PMID 38706271, PMID 38825840, PMID 10214756, PMID 10406987, PMID 10527042, PMID 10853813, PMID 10979878, PMID 11076832, PMID 11130527, PMID 11400186, PMID 11724917, PMID 12222941, PMID 12465055, PMID 12498954, PMID 12771261, PMID 12904089, PMID 1454205, PMID 15175402, PMID 15331239, PMID 15345186, PMID 15590952, PMID 15645531, PMID 15779234, PMID 15956161, PMID 16025231, PMID 16214880, PMID 16376913
2023 (11), 2016 (9), 2009 (6), 2015 (6), 2025 (6), 2017 (5), 2018 (5), 2008 (4), 2014 (4), 2019 (4), R01AG085029 (3), R01NS021062 (2), R01NS099535 (2), U01NS043128 (2), 1UG3NS133515-01A1 (1)